切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2021, Vol. 15 ›› Issue (10) : 797 -800. doi: 10.3877/cma.j.issn.1674-0785.2021.10.015

综述

MET靶点在非小细胞肺癌中的研究进展
张博1, 金波1,()   
  1. 1. 110001 沈阳,中国医科大学第一附属医院肿瘤内科
  • 收稿日期:2021-05-31 出版日期:2021-10-15
  • 通信作者: 金波

Progress in research of Met as a target in non-small cell lung cancer

Bo Zhang1, Bo Jin1,()   

  1. 1. Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China
  • Received:2021-05-31 Published:2021-10-15
  • Corresponding author: Bo Jin
引用本文:

张博, 金波. MET靶点在非小细胞肺癌中的研究进展[J/OL]. 中华临床医师杂志(电子版), 2021, 15(10): 797-800.

Bo Zhang, Bo Jin. Progress in research of Met as a target in non-small cell lung cancer[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(10): 797-800.

近年来,靶向治疗和免疫治疗显著提高了非小细胞肺癌患者的预后,其中,间质-上皮转化因子(c-MET或MET)在肺癌发生中起重要作用,影响癌细胞的增殖、侵袭、存活和血管生成,是非小细胞肺癌继表皮生长因子受体(EGFR)和间变性淋巴瘤激酶(ALK)之后的又一重要靶点。在非小细胞肺癌中,MET信号通路异常激活的机制包括MET或肝细胞生长因子(HGF)蛋白过表达、MET基因扩增、MET基因突变、MET重排以及下游信号或调节成分的异常。针对MET靶点的药物包括选择性酪氨酸激酶抑制剂(TKI)、非选择性TKI以及针对MET或者其配体HGF的抗体,同时新药物的耐药机制也值得我们进一步研究。

Recently, targeted therapy and immunotherapy have significantly improved the prognosis of patients with non-small cell lung cancer. In addition to epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), c-MET or MET is another important target for non-small cell lung cancer. MET plays an important role in the occurrence of lung cancer, affecting the proliferation, invasion, and angiogenesis of cancer cells. In non-small cell lung cancer, the mechanism of abnormal activation of the MET signaling pathway includes overexpression of MET or hepatocyte growth factor (HGF) protein, MET gene amplification, MET gene mutation, MET rearrangement, abnormal downstream signaling, and abnormal regulatory components. Drugs targeting MET include selective tyrosine kinase inhibitors (TKIs), non-selective TKIs, and antibodies against MET or its ligand HGF. Besides, the drug resistance mechanism to new drugs is also worthy of further study.

10
Bylicki O, Paleiron N, Assié JB, et al. Targeting the MET-signaling pathway in non-small-cell lung cancer: evidence to date [J]. OncoTargets Ther, 2020, 13: 5691-5706.
11
Reungwetwattana T, Liang Y, Zhu V, et al. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable [J]. Lung Cancer, 2017, 103: 27-37.
12
Le X, Heymach JV. New verse for a familiar song: small molecule inhibitors for MET exon 14 skipping non-small cell lung cancer [J]. Oncologist, 2020, 25(10): 822-825.
13
尹利梅, 卢铀. MET 14外显子跳跃突变在非小细胞肺癌中的研究进展 [J]. 中国肺癌杂志, 2018, 21(7): 553-559.
14
Wang Q, Yang S, Wang K, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer [J]. J Hematol Oncol, 2019, 12(1): 63.
15
Westover D, Zugazagoitia J, Cho BC, et al. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors [J]. Ann Oncol, 2018, 29(suppl_1): 10-19.
16
Scagliotti GV, Shuster D, Orlov S, et al. Tivantinib in combination with Erlotinib versus Erlotinib alone for EGFR-Mutant NSCLC: an exploratory analysis of the phase 3 MARQUEE study [J]. J Thorac Oncol, 2018, 13(6): 849-854.
17
Oxnard GR, Yang JC, Yu H, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer [J]. Ann Oncol, 2020, 31(4) :507-516.
18
Yin W, Cheng J, Tang Z, et al. MET amplification (MET/CEP7 Ratio ≥1.8) is an independent poor prognostic marker in patients with treatment-naive non-small-cell lung cancer [J]. Clin Lung Cancer, 2021, 22(4): 512-518.
19
Liang H, Wang M. MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF/c-Met axis [J]. Onco Targets Ther, 2020, 13: 2491-2510.
20
Miranda O, Farooqui M, Siegfried JM. Status of agents targeting the HGF/c-Met axis in lung cancer [J]. Cancers (Basel), 2018, 10(9): 280.
21
Salgia R. MET in lung cancer: biomarker selection based on scientific rationale [J]. Mol Cancer Ther, 2017, 16(4): 555-565.
22
Hong L, Zhang J, Heymach JV, et al. Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer [J]. Ther Adv Med Oncol, 2021, 13: 1758835921992976.
23
Landi L, Chiari R, Tiseo M, et al. Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): a phase Ⅱ, prospective, multicenter, two-arms trial [J]. Clin Cancer Res, 2019, 25(24): 7312-7319.
24
Markham A. Tepotinib: first approval [J]. Drugs, 2020, 80(8): 829-833.
25
Seto T, Ohashi K, Sugawara S, et al. Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study [J]. Cancer Sci, 2021, 112(4): 1556-1566.
26
Dhillon S. Capmatinib: first approval [J]. Drugs, 2020, 80(11) :1125-1131.
27
Vansteenkiste JF, Van De Kerkhove C, Wauters E, et al. Capmatinib for the treatment of non-small cell lung cancer [J]. Expert Rev Anticancer Ther, 2019, 19(8): 659-671.
28
Huang C, Zou Q, Liu H, et al. Management of non-small cell lung cancer patients with MET exon 14 skipping mutations [J]. Curr Treat Options Oncol, 2020, 21(4): 33.
29
Lu S, Fang J, Li X, et al. Once-daily Savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study [J]. Lancet Respir Med, 2021. doi: 10.1016/S2213-2600(21)00084-9. Online ahead of print.
30
Schöffski P, Blay JY, Ray-Coquard I. Cabozantinib as an emerging treatment for sarcoma [J]. Curr Opin Oncol, 2020, 32(4) : 321-331.
31
韩森, 马旭, 方健. 非小细胞肺癌MET基因突变的机制及靶向药物研究进展 [J]. 中国肺癌杂志, 2020, 23(7): 609-614..
32
Piper-Vallillo AJ, Halbert BT, Rangachari D, et al. Acquired resistance to Osimertinib plus Savolitinib is mediated by MET-D1228 and MET-Y1230 mutations in EGFR-mutated MET-amplified lung cancer [J]. JTO Clin Res Rep, 2020, 1(4): 100071.
1
Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update [J]. Discov Med, 2019, 27(148): 167-170.
2
Kumarakulasinghe NB, van Zanwijk N, Soo RA. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC) [J]. Respirology (Carlton, Vic.), 2015, 20(3): 370-378.
3
Aoki MN, Amarante MK, de Oliveira CEC, et al. Biomarkers in non-small cell lung cancer: perspectives of individualized targeted therapy [J]. Anticancer Agents Med Chem, 2018, 18(15): 2070-2077.
4
Santarpia M, Massafra M, Gebbia V, et al. A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations [J]. Transl Lung Cancer Res, 2021, 10(3): 1536-1556.
5
Pasquini G, Giaccone G. C-MET inhibitors for advanced non-small cell lung cancer [J]. Expert Opin Investig Drugs, 2018, 27(4):363-375.
6
Rebuzzi SE, Zullo L, Rossi G, et al. Novel emerging molecular targets in non-small cell lung cancer [J]. Int J Mol Sci, 2021, 22(5): 2625.
7
Guo R, Luo J, Chang J, et al. MET-dependent solid tumours - molecular diagnosis and targeted therapy, Nature reviews [J]. Clin Oncol, 2020, 17(9) :569-587.
8
Drilon A, Cappuzzo F, Ou SI, et al. Targeting MET in lung cancer: will expectations finally be MET? [J]. J Thorac Oncol, 2017, 12(1): 15-26.
9
俞晓晴, 徐艳珺, 范云. c-MET通路和抑制剂在非小细胞肺癌中的研究进展 [J]. 中国肺癌杂志, 2017, 20(4): 287-292.
[1] 刘琴, 刘瀚旻, 谢亮. 基质金属蛋白酶在儿童哮喘发生机制中作用的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 564-568.
[2] 吴伟宙, 王琼仁, 詹雄宇, 郑明星, 李亚县. 广东省医学会泌尿外科疑难病例多学科会诊(第16期)——左肾肉瘤样癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 525-529.
[3] 李勇, 彭天明, 王倩倩, 陈育纯, 蒲小勇, 刘久敏. 基于失巢凋亡相关基因的膀胱癌预后模型构建及分析[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 331-339.
[4] 李飞, 郑灶松, 吴芃, 谭万龙. 广东省医学会泌尿外科疑难病例多学科会诊(第16期)——延胡索酸水合酶缺陷型晚期肾细胞癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 410-414.
[5] 张礼江, 沈玲佳, 施我大. 倾向性评分匹配分析奥希替尼对晚期NSCLC 预后的影响[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 820-822.
[6] 杨慧, 郭丽娟, 冯晓丹, 李静, 黄成谋, 蔡兴锐, 覃英娇, 王远礼. 非小细胞肺癌铂类药物耐药mi RNA表达特征及预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 719-724.
[7] 赖淼, 景鑫, 李桂珍, 李怡. 非小细胞肺癌EGFR 突变亚型的临床病理和预后意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 731-737.
[8] 梁丽斯, 李洁, 贺帅, 来艳君, 刘铭, 张琳. MMP-9、MMP-2 及TLR4、HE4对非小细胞肺癌早期诊断意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 756-761.
[9] 赵蒙蒙, 黄洁, 余荣环, 王葆青. 过表达小GTP酶Rab32抑制非小细胞肺癌细胞侵袭性生长[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 512-518.
[10] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[11] 魏妙艳, 徐近. 合并远处转移胰腺癌系统性治疗的梳理和展望[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 644-650.
[12] 李永政, 孟煜凡, 樊知遥, 展翰翔. 胰腺神经内分泌肿瘤新辅助治疗研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 481-486.
[13] 陆思楠, 苏同荣, 张启逸. 索凡替尼转化治疗胰腺神经内分泌肿瘤肝转移一例并文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 526-530.
[14] 王光伟, 李桂莲, 王勇. 散发性静脉畸形的靶向治疗进展[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 380-385.
[15] 崔伟, 李静, 陈晓明, 张靖, 邓屹, 许荣德. 载药微球支气管动脉化疗栓塞术治疗非小细胞肺癌的研究进展[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 289-295.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?